Trevor Baglin

Private Equity Investor chez Medicxi Ventures (Jersey) Ltd.

Profil

Trevor is a Venture Advisor in the Medicxi investment team.
He co-founded XO1 (acquired by Janssen Pharmaceuticals) and Apcintex (acquired by Centessa Pharmaceuticals).
He is Chief Medical Officer for Apcintex and Z Factor (Centessa Companies).
Prior to joining Medicxi he was a clinician at Cambridge University Hospitals where he was also Director of Investigative Sciences.
His main research interests were in personalised risk profiling, developed from studying the gene-environment interaction leading to thrombosis, and the molecular basis of blood coagulation, which led to his interest in drug discovery and development.
He has published more than 300 clinical and scientific papers and led the production of many national and international guidelines.
Trevor served as President of the British Society for Haematology, President of the British Society for Haemostasis and Thrombosis and was a Founder of the European Congress for Thrombosis and Haemostasis.
He qualified in Medicine from Manchester University, was awarded his PhD from the University of Birmingham and Doctor of Medical Science from Cambridge University.

Postes actifs de Trevor Baglin

Sociétés	Poste	Début
Medicxi Ventures (Jersey) Ltd.	Private Equity Investor	01/01/2017

Anciens postes connus de Trevor Baglin

Sociétés	Poste	Fin
Z Factor Ltd.	Corporate Officer/Principal	-
SuperX Ltd.	Fondateur	-
XO1 Ltd.	Fondateur	-
ApcinteX Ltd.	Fondateur	-

Formation de Trevor Baglin

University of Birmingham	Doctorate Degree
University of Cambridge	Graduate Degree
The University of Manchester	Undergraduate Degree